Ident. | Authors (with country if any) | Title |
---|
001038 (2013) |
James B. Koprich [Canada] ; Philippe Huot [Canada] ; Susan H. Fox [Canada] ; Keith Jarvie [Canada] ; Anthony E. Lang [Canada] ; Philip Seeman [Canada] ; Jonathan M. Brotchie [Canada] | The effects of fast-off-D2 receptor antagonism on L-DOPA-induced dyskinesia and psychosis in parkinsonian macaques |
001072 (2013) |
Maria Gabriela Sanchez [Canada] ; Marc Morissette [Canada] ; Thérèse Di Paolo [Canada] | Estradiol and brain serotonin reuptake transporter in long-term ovariectomized parkinsonian monkeys |
001477 (2012) |
Susan H. Fox [Canada] ; Tom H. Johnston [Canada] ; Qin Li [République populaire de Chine] ; Jonathan Brotchie [Canada] ; Erwan Bezard [République populaire de Chine, France] | A critique of available scales and presentation of the non‐human primate dyskinesia rating scale |
001534 (2012) |
Golnasim Riahi [Canada] ; Marc Morissette [Canada] ; Daniel Levesque [Canada] ; Claude Rouillard [Canada] ; Pershia Samadi [Canada] ; Martin Parent [Canada] ; Thérèse Di Paolo [Canada] | Effect of chronic L-DOPA treatment on 5-HT1A receptors in parkinsonian monkey brain |
001778 (2011) |
James B. Koprich [Canada] ; Susan H. Fox [Canada] ; Tom H. Johnston [Canada] ; Allan Goodman [États-Unis] ; Bertrand Le Bourdonnec [États-Unis] ; Roland E. Dolle [États-Unis] ; Robert N. Dehaven [États-Unis] ; Diane L. Dehaven-Hudkins [États-Unis] ; Patrick J. Little [États-Unis] ; Jonathan M. Brotchie [Canada] | The selective mu‐opioid receptor antagonist adl5510 reduces levodopa‐induced dyskinesia without affecting antiparkinsonian action in mptp‐lesioned macaque model of Parkinson's disease |
001937 (2011) |
Bazoumana Ouattara [Canada] ; Laurent Gregoire [Canada] ; Marc Morissette [Canada] ; Fabrizio Gasparini [Suisse] ; Ivo Vranesic [Suisse] ; Graeme Bilbe [Suisse] ; Donald R. Johns [Suisse] ; Alex Rajput [Canada] ; Oleh. Hornykiewicz [Autriche] ; Ali H. Rajput [Canada] ; Baltazar Gomez-Mancilla [Suisse] ; Therese Di Paolo [Canada] | Metabotropic glutamate receptor type 5 in levodopa-induced motor complications |
001950 (2011) |
Anne M. Landau [Danemark, Canada] ; M. Mallar Chakravarty [Danemark, Canada] ; Campbell M. Clark [Canada] ; Athanasios P. Zis [Canada] ; Doris J. Doudet [Danemark, Canada] | Electroconvulsive Therapy Alters Dopamine Signaling in the Striatum of Non-human Primates |
001C07 (2010) |
Catharine A. Winstanley [États-Unis] ; Peter Olausson [États-Unis] ; Jane R. Taylor [États-Unis] ; J. David Jentsch [États-Unis] | Insight Into the Relationship Between Impulsivity and Substance Abuse From Studies Using Animal Models |
001C36 (2010) |
Tom H. Johnston [Canada] ; Anne Van Der Meij [Pays-Bas] ; Jonathan M. Brotchie [Canada] ; Susan H. Fox [Canada] | Effect of histamine H2 receptor antagonism on levodopa–induced dyskinesia in the MPTP‐macaque model of Parkinson's disease |
001C80 (2010) |
Marc Morissette [Canada] ; Pershia Samadi [Canada] ; ABDALLAH HADJ TAHAR [Canada] ; Nancy Belanger [Canada] ; Thérèse Di Paolo [Canada] | Striatal Akt/GSK3 signaling pathway in the development of L-Dopa-induced dyskinesias in MPTP monkeys |
001C85 (2010) |
Robert A. Hodgson [États-Unis] ; Paul J. Bedard [Canada] ; Geoffrey B. Varty [États-Unis] ; Tatiana M. Kazdoba [États-Unis] ; Therese Di Paolo [Canada] ; Michael E. Grzelak [États-Unis] ; Annamarie J. Pond [États-Unis] ; Abdallah Hadjtahar [Canada] ; Nancy Belanger [Canada] ; Laurent Gregoire [Canada] ; Aurelie Dare [Canada] ; Bernard R. Neustadt [États-Unis] ; Andrew W. Stamford [États-Unis] ; John C. Hunter [États-Unis] | Preladenant, a selective A2A receptor antagonist, is active in primate models of movement disorders |
001D20 (2010) |
Bazoumana Ouattara [Canada] ; Fabrizio Gasparini [Suisse] ; Marc Morissette [Canada] ; Laurent Gregoire [Canada] ; Pershia Samadi [Canada] ; Baltazar Gomez-Mancilla [Suisse] ; Thérèse Di Paolo [Canada] | Effect of L-Dopa on metabotropic glutamate receptor 5 in the brain of parkinsonian monkeys |
001D36 (2010) |
B. Ouattara [Canada] ; D. Hoyer [Suisse] ; L. Gregoire [Canada] ; M. Morissette [Canada] ; F. Gasparini [Suisse] ; B. Gomez-Mancilla [Suisse] ; T. Di Paolo [Canada] | CHANGES OF AMPA RECEPTORS IN MPTP MONKEYS WITH LEVODOPA-INDUCED DYSKINESIAS |
002379 (2008) |
Anthony P. Nicholas [États-Unis] ; Farah D. Lubin [États-Unis] ; Penelope J. Hallett [États-Unis] ; Padmapriya Vattem [États-Unis] ; Paula Ravenscroft [Royaume-Uni] ; Erwan Bezard [France] ; SHAOBO ZHOU [Royaume-Uni] ; Susan H. Fox [Canada] ; Jonathan M. Brotchie [Canada] ; J. David Sweatt [États-Unis] ; David G. Standaert [États-Unis] | Striatal histone modifications in models of levodopa-induced dyskinesia |
002528 (2007) |
Penelope J. Hallett [États-Unis] ; J. M. Brotchie [Canada] | Striatal delta opioid receptor binding in experimental models of Parkinson's disease and dyskinesia |
002805 (2006) |
Marc Morissette [Canada] ; Mehdi Dridi [Canada] ; Frédéric Calon [Canada] ; Abdallah Hadj Tahar [Canada] ; Leonard T. Meltzer [États-Unis] ; Paul J. Bédard [Canada] ; Thérèse Di Paolo [Canada] | Prevention of levodopa‐induced dyskinesias by a selective NR1A/2B N‐methyl‐D‐aspartate receptor antagonist in parkinsonian monkeys: Implication of preproenkephalin |
002851 (2006) |
Pershia Samadi [Canada] ; Laurent Grégoire [Canada] ; Claude Rouillard [Canada] ; Paul J. Bédard [Canada] ; Thérèse Di Paolo [Canada] ; Daniel Lévesque [Canada] | Docosahexaenoic acid reduces levodopa‐induced dyskinesias in 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine monkeys |
002905 (2006) |
J. Miklossy [Canada] ; D. D. Doudet [Canada] ; C. Schwab [Canada] ; S. Yu [Canada] ; E. G. Mcgeer [Canada] ; P. L. Mcgeer [Canada] | Role of ICAM-1 in persisting inflammation in parkinson disease and MPTP monkeys |
002914 (2006) |
Carl Julien [Canada] ; Line Berthiaume [Canada] ; Abdallah Hadj-Tahar [Canada] ; Ali H. Rajput [Canada] ; Paul J. Bedard [Canada] ; Thérèse Di Paolo [Canada] ; Pierre Julien [Canada] ; Frédéric Calon [Canada] | Postmortem brain fatty acid profile of levodopa-treated Parkinson disease patients and parkinsonian monkeys |
002939 (2006) |
Maryka Quik [États-Unis] ; Neeraja Parameswaran [États-Unis] ; Sarah E. Mccallum [États-Unis] ; Tanuja Bordia [États-Unis] ; SHANSHAN BAO [États-Unis] ; Alison Mccormack [États-Unis] ; Amy Kim [États-Unis] ; Rachel F. Tyndale [Canada] ; J. William Langston [États-Unis] ; Donato A. Di Monte [États-Unis] | Chronic oral nicotine treatment protects against striatal degeneration in MPTP-treated primates |
002947 (2006) |
Naomi P. Visanji [Canada] ; Mark J. Millan [France] ; Jonathan M. Brotchie [Canada] | Actions at sites other than D3 receptors mediate the effects of BP897 on L-DOPA-induced hyperactivity in monoamine-depleted rats |
002B30 (2005) |
Pershia Samadi [Canada] ; Laurent Gregoire [Canada] ; Arash Rassoulpour [États-Unis] ; Paolo Guidetti [Canada] ; Emanuela Izzo [Italie] ; Robert Schwarcz [États-Unis] ; Paul J. Bedard [Canada] | Effect of kynurenine 3-hydroxylase inhibition on the dyskinetic and antiparkinsonian responses to levodopa in parkinsonian monkeys |
002B51 (2005) |
Tom H. Johnston [Canada] ; Joohyung Lee [Canada] ; Jordi Gomez-Ramirez [Canada] ; Susan H. Fox [Canada] ; Jonathan M. Brotchie [Canada] | A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease |
002D16 (2004) |
D. J. Doudet [Canada] ; M. L. Cornfeldt [États-Unis] ; C. R. Honey [Canada] ; A. W. Schweikert [États-Unis] ; R. C. Allen [États-Unis] | PET imaging of implanted human retinal pigment epithelial cells in the MPTP-induced primate model of parkinson's disease |
002E23 (2003) |
Antonio P. Strafella [Canada] ; Toma S Paus [Canada] ; Maria Fraraccio [Canada] ; Alain Dagher [Canada] | Striatal dopamine release induced by repetitive transcranial magnetic stimulation of the human motor cortex |
002E38 (2003) |
Patrick L. Mcgeer [Canada] ; Claudia Schwab ; Andre Parent [Canada] ; Doris Doudet | Presence of reactive microglia in monkey substantia nigra years after 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine administration |
002F15 (2003) |
Pershia Samadi [Canada] ; Laurent Gregoire [Canada] ; Paul J. Bedard [Canada] | Opioid antagonists increase the dyskinetic response to dopaminergic agents in parkinsonian monkeys: interaction between dopamine and opioid systems |
002F16 (2003) |
Michael P. Hill [Royaume-Uni] ; Erwan Bezard [France] ; Steven G. Mcguire [Royaume-Uni] ; Alan R. Crossman [Royaume-Uni] ; Jonathan M. Brotchie [Canada] ; Ann Michel [Belgique] ; Renee Grimee [Belgique] ; Henrik Klitgaard [Belgique] | Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmoset |
002F44 (2003) |
Pierre J. Blanchet [États-Unis, Canada] ; Spiros Konitsiotis [États-Unis, Grèce] ; Hideki Mochizuki [États-Unis, Japon] ; Ryszard Pluta [États-Unis] ; Dwaine F. Emerich [États-Unis] ; Thomas N. Chase [États-Unis] ; M. Maral Mouradian [États-Unis] | Complications of a trophic xenotransplant approach in parkinsonian monkeys |
002F47 (2003) |
Nancy Belanger [Canada] ; Laurent Gregoire [Canada] ; ABDALLAH HADJ TAHAR [Canada] ; Paul J. Bedard [Canada] | Chronic treatment with small doses of cabergoline prevents Dopa-induced dyskinesias in Parkinsonian monkeys |
003078 (2002) |
James E. Holden [États-Unis] ; Salma Jivan [Canada] ; Thomas J. Ruth [Canada] ; Doris J. Doudet [Canada] | In vivo receptor assay with multiple ligand concentrations: An equilibrium approach |
003103 (2002) |
Frédéric Calon [Canada] ; Marc Morissette [Canada] ; Othman Ghribi [Canada] ; Martin Goulet [Canada] ; Richard Grondin [Canada] ; Pierre J. Blanchet [Canada] ; Paul J. Bedard [Canada] ; Thérèse Di Paolo [Canada] | Alteration of glutamate receptors in the striatum of dyskinetic 1 -methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys following dopamine agonist treatment |
003332 (2001) |
ABDALLAH HADJ TAHAR [Canada] ; Anna Ekesbo [Suède] ; Laurent Gregoire [Canada] ; Evelyne Bangassoro [Canada] ; Kjell A. Svensson [États-Unis] ; Joakim Tedroff [Suède] ; Paul J. Bedard [Canada] | Effects of acute and repeated treatment with a novel dopamine D2 receptor ligand on L-DOPA-induced dyskinesias in MPTP monkeys |
003512 (2000) |
Frédéric Calon [Canada] ; Abdallah Hadj Tahar [Canada] ; Pierre J. Blanchet [Canada] ; Marc Morissette [Canada] ; Richard Grondin [Canada] ; Martin Goulet [Canada] ; Jean-Pierre Doucet [Canada] ; George S. Robertson [Canada] ; Eric Nestler [États-Unis] ; Thérèse Di Paolo [Canada] ; Paul J. Bédard [Canada] | Dopamine-receptor stimulation: biobehavioral and biochemical consequences |
003549 (2000) |
Y. L. Xue [République populaire de Chine] ; Z. F. Wang [République populaire de Chine] ; D. G. Zhong [République populaire de Chine] ; X. Cui [République populaire de Chine] ; X. J. Li [République populaire de Chine] ; X. J. Ma [République populaire de Chine] ; L. N. Wang [République populaire de Chine] ; K. Zhu [République populaire de Chine] ; A. M. Sun [Canada] | Xenotransplantation of microencapsulated bovine chromaffin cells into hemiparkinsonian monkeys |
003557 (2000) |
ABDALLAH HADJ TAHAR [Canada] ; Laurent Gregoire [Canada] ; Evelyne Bangassoro [Canada] ; Paul J. Bedard [Canada] | Sustained cabergoline treatment reverses levodopa-induced dyskinesias in parkinsonian monkeys |
003562 (2000) |
M. Goulet [Canada] ; R. Grondin [Canada] ; M. Morissette [Canada] ; S. Maltais [Canada] ; P. Falardeau [Canada] ; P. J. Bedard [Canada] ; T. Di Paolo [Canada] | Regulation by chronic treatment with cabergoline of dopamine D1 and D2 receptor levels and their expression in the striatum of Parkinsonian-Monkeys |
003578 (2000) |
F. Calon [Canada] ; R. Grondin [Canada] ; M. Morissette [Canada] ; M. Goulet [Canada] ; P. J. Blanchet [Canada] ; T. T. Di Paolo [Canada] ; P. J. Bedard [Canada] | Molecular basis of levodopa-induced dyskinesias |
003596 (2000) |
ABDALLAH HADJ TAHAR [Canada] ; N. Belanger [Canada] ; E. Bangassoro [Canada] ; L. Gregoire [Canada] ; P. J. Bedard [Canada] | Antidyskinetic effect of JL-18, a clozapine analog, in parkinsonian monkeys |
003600 (2000) |
F. Calon [Canada] ; M. Morissette [Canada] ; M. Goulet [Canada] ; R. Grondin [Canada] ; P. J. Blanchet [Canada] ; P. J. Bedard [Canada] ; T. Di Paolo [Canada] | 125I-CGP 64213 binding to GABAB receptors in the brain of monkeys : Effect of MPTP and dopaminomimetic treatments |
003681 (1999) |
Frédéric Calon ; Marc Morissette ; Martin Goulet ; Richard Grondin ; Pierre J. Blanchet ; Paul J. Bédard ; Thérèse Di Paolo [Canada] | Chronic D1 and D2 dopaminomimetic treatment of MPTP-denervated monkeys: effects on basal ganglia GABAA/benzodiazepine receptor complex and GABA content |
003797 (1999) |
Juan Fernandez-Ruiz [États-Unis] ; Doris Doudet [Canada] ; Thomas G. Aigner [États-Unis] | Spatial memory improvement by levodopa in parkinsonian MPTP-treated monkeys |
003827 (1999) |
V. D. Doan [Canada] ; R. Grondin [Canada] ; ABDALLAH HADJ TAHAR [Canada] ; L. Gregoire [Canada] ; P. J. Bedard [Canada] | Effect of the selective D1 antagonists SCH 23390 and NNC 01-0112 on the delay, duration, and improvement of behavioral responses to dopaminergic agents in MPTP-treated monkeys |
003829 (1999) |
R. Grondin [Canada] ; M. Goulet [Canada] ; M. Morissette [Canada] ; P. J. Bedard [Canada] ; T. Di Paolo [Canada] | Dopamine D1 receptor mRNA and receptor levels in the striatum of MPTP monkeys chronically treated with SKF-82958 |
003832 (1999) |
R. Grondin [Canada] ; V. D. Doan ; L. Gregoire ; P. J. Bedard | D1 receptor blockade improves L-dopa-induced dyskinesia but worsens parkinsonism in MPTP monkeys |
003839 (1999) |
R. Grondin [Canada] ; P. J. Bedard [Canada] ; A. Hadj Tahar [Canada] ; L. Gregoire [Canada] ; A. Mori [Japon] ; H. Kase [Japon] | Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys |
003B34 (1997) |
M. Goulet [Canada] ; M. Morissette [Canada] ; F. Calon [Canada] ; P. J Blanchet [Canada] ; P. Falardeau [Canada] ; P. J Bédard [Canada] ; T. Di Paolo [Canada] | Continuous or pulsatile chronic D2 dopamine receptor agonist (U91356A) treatment of drug-naive 4-phenyl-1,2,3,6-tetrahydropyridine monkeys differentially regulates brain D1 and D2 receptor expression: in situ hybridization histochemical analysis |
003C38 (1997) |
R. Levy [France] ; L.-N. Hazrati [Canada] ; M.-T. Herrero [France, Espagne] ; M. Vila [France] ; O.-K. Hassani [France] ; M. Mouroux [France] ; M. Ruberg [France] ; H. Asensi [Espagne] ; Yves Agid [France] ; J. Feger [France] ; J. A. Obeso [Espagne] ; A. Parent [Canada] ; E. C. Hirsch [France] | Re-evaluation of the functional anatomy of the basal ganglia in normal and Parkinsonian states |
003C40 (1997) |
R. Grondin [Canada] ; P. J. Bedard [Canada] ; D. R. Britton [États-Unis] ; K. Shiosaki [États-Unis] | Potential therapeutic use of the selective dopamine D1 receptor agonist, A-86929 : An acute study in parkinsonian levodopa-primed monkeys |
003C61 (1997) |
D. J. Doudet [Canada] ; G. L. Y. Chan [Canada] ; J. E. Holden [États-Unis] ; K. S. Morrison [Canada] ; R. J. Wyatt [États-Unis] ; T. J. Ruth [Canada] | Effects of catechol-O-methyltransferase inhibition on the rates of uptake and reversibility of 6-fluoro-L-dopa trapping in MPTP-induced Parkinsonism in monkeys |
003D21 (1996) |
Jean-Jacques Soghomonian [Canada] ; Sophie Pedneault [Canada] ; Pierre J. Blanchet [Canada] ; Martin Goulet [Canada] ; Thérèse Di Paolo [Canada] ; Paul J. Bédard [Canada] | l-DOPA regulates glutamate decarboxylases mRNA levels in MPTP-treated monkeys |